Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2033

Annual patent cliff calendar for 2033 — US pharmaceutical patents by expiration date.

Patents
1,330

Quick answer

1,330 indexed pharmaceutical patents have expiration dates in 2033. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 8378084

    Fusion molecule based on novel TAA variant

    The Regents of the University of California · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8378071

    Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8377959

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    ACADIA Pharmaceuticals Inc. · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8377965

    Crystalline forms of a biphenyl compound

    Theravance, Inc. · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8377945

    Small molecule inhibitors of spleen tyrosine kinase (SYK)

    Rigel Pharmaceuticals, Inc. · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8377926

    Aminopyridine kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8377924

    Protein kinase C inhibitors and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8377872

    Cyclic P3 tripeptide hepatitis C serine protease inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8377884

    Variants of C-type natriuretic peptides

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8377637

    MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-17-3P

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8377966

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance, Inc. · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8378107

    Heteroaryl antagonists of prostaglandin D2 receptors

    Panmira Pharmaceuticals, LLC · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8383647

    Quinoline derivative

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8383669

    Crystalline form of a 3-phenoxymethylpyrrolidine compound

    Theravance, Inc. · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8383633

    Aminopyrimidines useful as kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8383628

    Pyridyl derivatives and their use as therapeutic agents

    Xenon Pharmaceuticals Inc. · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8383589

    Aegyptin and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8383580

    Methods of administering lipocalins to treat metabolic disorders and cardiovascular diseases

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8383576

    LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized

    REGENERX BIOPHARMACEUTICALS, INC. · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8383388

    Modified coagulation factor IX polypeptides and use thereof for treatment

    Catalyst Biosciences, Inc. · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8383133

    Conjugates of Plasmodium falciparum surface proteins as malaria vaccines

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8383380

    Segmented polymers and their conjugates

    Nektar Therapeutics · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8383132

    Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use

    The Regents of the University of California · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8383360

    Methods of diagnosing and treating autism

    The Regents of the University of California · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8383102

    Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens

    The United States of America, as represented by the Secretary of Agriculture · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8383099

    Adoptive cell therapy with young T cells

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8383654

    Heterocyclic antagonists of prostaglandin D2 receptors

    Panmira Pharmaceuticals, LLC · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8383817

    Benztropine compounds and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8383645

    Stable laquinimod preparations

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8383113

    Anti-ADDL antibodies and uses thereof

    Northwestern University · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8383583

    Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8383805

    RNAi modulation of SCAP and therapeutic uses thereof

    The Board of Regents of the University of Texas System · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8383785

    Anti-bacterial activity of 9-hydroxy derivatives of 6,11-bicyclolides

    Enanta Pharmaceuticals, Inc. · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8383858

    Processes and intermediates for preparing steric compounds

    Vertex Pharmaceuticals Incorporated · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8383665

    Immunomodulatory compositions

    Summit (Wales) Limited · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8383093

    Subcutaneous delivery of poly(oxazoline) conjugates

    Serina Therapeutics, Inc. · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8388930

    Diagnosis and assessment of skeletal related disease using calcium 41

    The Regents of the University of California · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8389759

    Oligomer-anticholinergic agent conjugates

    Nektar Therapeutics · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8389679

    Targeted antimicrobial moieties

    The Regents of the University of California · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8391959

    Composition for improving efficiency of drug delivery

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8388956

    Interleukin-1 alpha antibodies and methods of use

    XBIOTECH INC. · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8389736

    Compounds having activity in correcting mutant-CFTR processing and uses thereof

    The Regents of the University of California · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8389727

    Solid forms of N-(4-(7-Azabicyclo[2.2.1]Heptan-7-yl)-2-Trifluoromethyl)Phenyl)-4-Oxo-5-(Trifluoromethyl)-1,4-Dihydroquinoline-3-Carboxamide

    Vertex Pharmaceuticals Incorporated · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8388643

    Bioabsorbable polymeric implants and a method of using the same to create occlusions

    The Regents of the University of California · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8389731

    Chiral pyrrolidine core compounds en route to inhibitors of nitric oxide synthase

    Northwestern University · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8389515

    2,4-pyrimidinediamine compounds and prodrugs and their uses

    Rigel Pharmaceuticals, Inc. · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8389502

    Stabilized steroid composition and method for its preparation

    Precision Dermatology, Inc. · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8389478

    Methods and compositions for treating neurodegenerative disorders and Alzheimer's disease and improving normal memory

    The Regents of the University of California · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2033?

1,330 published patents in our USPTO index have expiration dates falling in calendar year 2033.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.